Anivive’s Oral Lymphoma Drug Laverdia-CA1 Receives FDA Conditional Approval for Dogs
The FDA has conditionally approved Anivive’s Laverdia-CA1 (verdinexor), the first oral SINE-based therapy designed for canine lymphoma, expanding at-home treatment options for both B-cell and T-cell disease.